Abstract
In this study, the records of 276 adult patients with recurrent glioblastoma (GBM) treated at recurrence at our institution between 2004 and 2006 were reviewed for progression-free survival (PFS), overall survival (OS), and toxicity. At recurrence, all patients underwent systemic treatment with temozolomide (200 mg/sqm on days 1–5 every 28 days) until tumor progression. Patients, whose tumor was judged resectable without risk of adjunctive neurological deficit, underwent a second surgery with or without positioning of a Rickam/Ommaya reservoir. The reservoir was used for locoregional chemotherapy with mitoxantrone. Two hundred seventy-six rGBL patients (pts) were divided into three subgroups: A 161 pts treated only with temozolomide, B 50 pts re-operated-on +temozolomide, and C 65 pts re-operated on + temozolomide + locoregional CHT. For group A, the 6 month PFS and 6 month survival (ST) were 39.3 and 43%, respectively, with a median survival time (mST) of 5 months (range 4–6) and 25% of pts alive at 9 months. For group B, the 6 month PFS and 6 month survivors were 64 and 74.1%, respectively, with a mST of 8 months (range 6–10) and 25% of pts alive at 12 months. For group C, the 6 month PFS and 6 month survivors were 70.7 and 87.7%, respectively, with a mST of 11 months (range 9–13) and 25% of pts alive at 18 months (A vs. B vs. C, log-rank P < 0.001) (B vs. C, P = 0.041) (A vs. B P = 0.009). Cox proportional hazard model was used to obtain Hazard Ratio (HR) for type of treatment corrected by age and time (in months) between diagnosis and first recurrence: second tumor debulking was statistically effective for survival, reducing by 36% the risk of death (HR = 0.64; 0.46–0.89), but the most significant favorable prognostic factor for survival was the local delivery of mitoxantrone which reduced the risk of death to 50% (HR = 0.50; 0.38–0.68).
Similar content being viewed by others
References
Walker MD, Green SB, Byar DP et al (1980) Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323–1327
Fine HA, Dear KBG, Loeffler YS et al (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585–2597
Tatter SB (2002) Recurrent malignant glioma in adults. Curr Treat Options Oncol 3:509–524
Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
Esteller M, Hamilton SR, Burger PC et al (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793–797
Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003
Huncharek M, Muscat J (1998) Treatment of recurrent high grade astrocytoma; results of a systematic review of 1415 patients. Anticancer Res 18:1303–1312
Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593
Brada M, Hoang-Xuan K, Rampling R et al (2002) Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol 12:149–150
Dillman RO, Duma CM, Schiltz PM et al (2004) Intracavitary placement of autologous lymphokine-activated killer (LAK) cells after resection of recurrent glioblastoma. J Immunother 27:398–404
Lidar Z, Mardor Y, Jonas T et al (2004) Convection-enhanced delivery of paclitaxel for the treatment of recurrent malignant glioma: a phase I/II clinical study. J Neurosurg 100:472–479
Chan TA, Weingart JD, Parisi M (2005) Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys 62:1133–1139
Di Meco F, Li KW, Tyler BM et al (2002) Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats. J Neurosurg 5:1173–1178
Brem H, Piantadossi S, Burger P et al (1995) Placebo controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 345:1008–1012
Westphal M, Ram Z, Riddle V et al (2006) On behalf of the executive committee of the Gliadel study group. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 148:269–275
Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 5:79–88
Senkal M, Tonn JC, Schonmayr R et al (1997) Mitoxantrone-induced DNA strand breaks in cell-cultures of malignant human astrocytoma and glioblastoma tumors. J Neurooncol 32:203–208
Perego P, Boiardi A, Carenini N et al (1994) Characterisation of an established human malignant glioblastoma cell line and its response to conventional drugs. J Cancer Res Clin Oncol 120:585–592
Nikkhah G, Tonn JC, Hoffmann O (1992) The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: evaluation of patient- and drug-specific variables. J Neurooncol 13:13–24
Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H (1999) Chemosensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol 125:481–486
Ferroli P, Broggi M, Franzini A et al (2006) Surgifoam and mitoxantrone in the glioblastoma multiforme postresection cavity: the first step of locoregional chemotherapy through an ad hoc-placed catheter: technical note. Neurosurgery 59:433–434
Boiardi A, Eoli M, Salmaggi A et al (2005) A systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma. J Neurooncol 75:215–220
Boiardi A, Eoli M, Salmaggi A et al (2003) New approach in delivering chemotherapy: locoregional treatment for recurrent glioblastoma (rGBM). J Exp Clin Cancer Res 22:123–127
MacDonald DR, Cascino TL, Clifford S (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5:649–655
Nieder C, Grosu AL, Molls M (2000) A comparison of treatment results for recurrent malignant gliomas. Cancer Treat Rev 26:397–409
Osoba D, Brada M, Prados MD (2000) Effect of disease burden on health-related quality of life in patients with malignant gliomas. Neuro-Oncology 4:221–228
Abrey LE (2005) Concomitant chemoradiotherapy followed by adjuvant temozolomide improves survival in glioblastoma multiforme. Curr Neurol Neurosci Rep 5:167–168
Gaya A, Rees J, Greenstein A et al (2002) The use of temozolomide in recurrent malignant gliomas. Cancer Treat Rev 28:115–120
Sipos L, Vitanovics D, Afra D (2001) Treatment of recidive malignant gliomas with temozolomide. Ann Oncol 12:259–266
Sipos L, Vitanovics D, Afra D (2002) Treatment of recidive malignant gliomas with temozolomide. Orv Hetil 143(21):1201–1204
Sipos L, Afra D (1997) Re-operations of supratentorial anaplastic astrocytomas. Acta Neurochir (Wien) 139:99–104
Hau P, Baumgart U, Pfeifer K et al (2003) Salvage therapy in patients with glioblastoma: is there any benefit? Cancer 98:2678–2686
Soults CB, Canute GS, Ryken TC (1998) Evidence-based review of the role of reoperation in the management of malignant glioma. Neurosurg Focus 15:11–16
Guyotat J, Signorelli F, Frappaz D et al (2000) Is reoperation for recurrence of glioblastoma justified? Oncol Rep 7:899–904
Barker FG, Chang SM, Gutin PH et al (1998) Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 42:709–720
Pinsker M, Lumenta C (2001) Experiences with reoperation on recurrent glioblastoma multiforme. Zentralbl Neurochir 62:43–47
Ammirati M, Galicich JH, Arbit E (1987) Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21:607–614
Dirks P, Bernstein M, Muller PJ et al (1993) The value of reoperation for recurrent glioblastoma. Can J Surg 36:271–275
Gabayan AJ, Green SB, Sanan A et al (2006) GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery 59:821–826
Combs SE, Thilmann C, Edler L (2005) Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 23:8863–8869
Shrieve DC, Alexander E, Wen PY (1995) Comparison of stereotactic radiosurgery and brachytherapy in the treatment of recurrent glioblastoma multiforme. Neurosurgery 36:275–282
Riva P, Franceschi G, Riva N et al (2000) Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med 27:601–609
Paganelli G, Bartolomei M, Ferrari M (2001) Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm 16:227–235
Akabani G, Reardon DA, Coleman RE et al (2005) Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study. J Nucl Med 46:1042–1051
Hayes RL, Koslow M, Hiesiger EM (1995) Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma. Cancer 76:840–852
Lawson HC, Sampath P, Bohan E et al (2007) Interstitial chemotherapy for malignant gliomas: the Johns Hopkins experience. J Neurooncol 83:61–70
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Boiardi, A., Silvani, A., Eoli, M. et al. Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?. J Neurooncol 88, 105–113 (2008). https://doi.org/10.1007/s11060-008-9540-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11060-008-9540-6